- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004364
Study of Novel Types of Familial Diabetes Insipidus
OBJECTIVES:
I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
Study Overview
Detailed Description
PROTOCOL OUTLINE: Participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (DI). The studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of DDAVP. If clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed.
Linkage analysis is performed for all participants; kindreds with the Marfan-like syndrome are also studied for the fibrillin-1 genotype.
Participants determined to have DI are treated with desmopressin for 2 days.
Study Type
Enrollment
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Familial diabetes insipidus (DI) in atypical or novel form, e.g.: Dipsogenic DI Neurohypophyseal DI
- Affected and unaffected members of kindreds eligible
Study Plan
How is the study designed?
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Gary L. Robertson, Northwestern University
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 199/11939
- NU-570
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Insipidus
-
Emory UniversityTerminated
-
Lady Davis InstituteCompletedLithium Use, Nephrogenic Diabetes InsipidusCanada
-
Ferring PharmaceuticalsCompletedCentral Diabetes InsipidusJapan
-
Universitair Ziekenhuis BrusselCompletedNephrogenic Diabetes InsipidusBelgium
-
University Hospital, Basel, SwitzerlandRecruitingCentral Diabetes Insipidus (cDI)Switzerland
-
Elizabeth Austen LawsonNot yet recruitingCentral Diabetes InsipidusUnited States
-
University of Colorado, DenverUniversity of AarhusCompletedNephrogenic Diabetes InsipidusUnited States, Denmark
-
National Center for Research Resources (NCRR)Northwestern UniversityCompletedDiabetes Insipidus | Diabetes Insipidus, NeurohypophysealUnited States
-
Mayo ClinicHopital du Sacre-Coeur de MontrealRecruitingAutosomal Dominant Polycystic Kidney Disease | Nephrogenic Diabetes Insipidus | Acquired Nephrogenic Diabetes Insipidus | Congenital Nephrogenic Diabetes InsipidusUnited States
-
Radboud University Medical CenterNot yet recruitingBipolar Disorder | Concentration Ability Impaired | Nephrogenic Diabetes Insipidus | Lithium Toxicities | Lithium - Induced NephropathyNetherlands
Clinical Trials on desmopressin
-
University Hospital, GhentCompletedEnuresis | PolyuriaBelgium
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompletedCentral Diabetes InsipidusJapan
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompleted
-
University of Kansas Medical CenterWithdrawnKidney DamageUnited States
-
Laboratorio Elea Phoenix S.A.Completed
-
Groupe Maladies hémorragiques de BretagneRecruitingDesmopressin | Hemophilia A, Mild | Factor VIIIFrance
-
Emory UniversityCompletedHemophilia AUnited States